Table 1 Stakeholder characteristics

Patient perspective

5 interviews:

4 with parents of patients with SMA

1 with a representative of the patient organisation

Clinical perspective

3 interviews:

2 with nurses involved in SMA treatment in the SMA Centre of Expertise in Utrecht

1 with a physician involved in SMA treatment in the SMA Centre of Expertise in Utrecht

Policy perspective

5 interviews:

3 with representatives of the governmental organisations involved (5 persons, Ministry of Public Health and Sports and the Dutch Healthcare Institute)

1 with representative of the pharmaceutical company involved (Biogen)

1 with a representative of one of the largest health insurance companies (Zilveren Kruis)